Business

Bintai Kinden partner signs deal to develop, commercialise Covid-19 vaccines

Generex Biotechnology Corporation enters agreement with Chinese Centre for Disease Control and Prevention

Updated 6 years ago · Published on 05 Nov 2020 4:14PM

Bintai Kinden partner signs deal to develop, commercialise Covid-19 vaccines
Bintai Kinden had earlier signed an agreement with Generex for the distribution and licensing of their Covid-19 vaccine in Malaysia. – AFP pic, November 5, 2020

KUALA LUMPUR – Bintai Kinden Corporation Bhd’s partner, Generex Biotechnology Corporation, has signed a framework agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China.

The agreement was signed with the Chinese Centre for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd.

In a statement today, Bintai Kinden said under the agreement, Generex would receive upfront development fees and back-end licensing payments, while the partners would undertake research and development and pay 100% of the funding required for the vaccine's commercial approval of the Ii-Key-CoV-2 vaccine.

This includes laboratory work, manufacturing, regulatory filings, and the clinical development programme for regulatory approval of the vaccine in China.

The Ii-Key-SARS-CoV-2 vaccine was designed as a “complete vaccine” with the potential to induce highly specific T-cell and antibody immune responses, also providing protective immunity with long-lasting immunologic memory against SARS-CoV-2 and other pandemic threats.

Managing director Ong Choon Lui said the partnership reaffirmed Ii-Key's technological potential to develop safe and effective vaccines.

“The involvement of China’s state-owned fund and cooperation at the highest government level through the China CDC increases the likelihood of success of vaccine commercialisation efforts,” he said.

Bintai Kinden said its subsidiary, Bintai Healthcare Sdn Bhd, had signed an agreement with Generex and its subsidiary, NuGenerex Immuco-Oncology Inc in October for the distribution and licensing of their Covid-19 vaccine in Malaysia.

The agreement granted Bintai Healthcare exclusive rights to distribute, sell, and commercialise the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand, and Vietnam.

“It will also have the right of first refusal to commercially exploit the vaccine within New Zealand, Australia and the global halal market,” it added.

China CDC is a governmental and national-level technical organisation specialising in disease control and prevention and public health, while Beijing Guoxin Haixiang is a limited partnership established to fund the research and development efforts of the partnership.

Meanwhile, Beijing Youfeng, also known as the China High-Tech Industrialisation Research Society Public Health Working Committee, provides development strategy consulting and design, project implementation, and management. – Bernama, November 5, 2020

Related News

Opinion / 5d

Honey Trap: Western media response to Jensen Huang and the latest China spy story

Opinion / 2w

Will the AI bubble burst?

Events / 3w

Shanghai trade fair returns to KL with 500 exhibitors in November

Malaysia / 1mth

Dr Noor Hisham denies claims that the Pfizer vaccine caused deaths

Malaysia / 1mth

PM Anwar loses beloved elder brother; Idrus Ibrahim passes away

Malaysia / 1mth

Anwar asks Loke to reconsider resignation over Najib pardon

Spotlight

Malaysia

Khalid urges PAS to ditch Umno alliance and support Anwar

By Alfian Z.M. Tahir

Malaysia

Najib’s house arrest: Govt, AG, Hannah opposed conditional pardon, minutes show

Malaysia

Former Negeri Sembilan exco members end legal fight over removal

Business

Nvidia rules out Jensen Huang comeback as quarterly revenue doubles to US$115b

Malaysia

Indonesia should compensate Malaysians for the prolonged haze – Guan Eng

By Ian McIntyre

Malaysia

Padang Rengas dispute exposes challenge facing possible BN-PN pact

You may be interested

Business

Oil slides to near three-month lows on supply glut concerns

Business

Oil steadies as Middle East tensions collide with supply glut concerns; ringgit edges weaker

Business

Data centre projects to generate 3,523 high-skilled jobs

Business

Seventy-seven O&G companies record export earnings under industry blueprint - Akmal

Business

Nvidia rules out Jensen Huang comeback as quarterly revenue doubles to US$115b

Business

Malaysia expands Islamic finance to fund climate resilience with new Sukuk PRISMA framework